

Proceedings of the Twelfth Biennial Symposium

The American Academy of Veterinary Pharmacology and Therapeutics

Denver, CO
May 22-24, 2001

Edited by Cory Langston

Preface

The Twelfth Biennial Symposium of the American Academy of Veterinary Pharmacology and Therapeutics (AAVPT) was held at the Adam's Mark Hotel in Denver, Colorado from May 22 to 24 of 2001. The program was divided into basic science and clinical pharmacology sections.

The first day of the basic science program was devoted to a workshop addressing the 1996 FDA-CVM Bioequivalence Guidelines and whether the criteria were too rigid. The results from this effort were subsequently published in the *Journal of Veterinary Pharmacology and Therapeutics* 25(3), 201-220, 2002 and are reproduced in these proceedings with permission from the publisher. The second day of the basic science program contained presentations on the supply and demand for veterinary clinical pharmacologists within industry and academia as well as pharmaceutical formulation issues unique to veterinary medicine.

The clinical portion of the program, cosponsored by the American College of Veterinary Clinical Pharmacology (ACVCP) and the American College of Veterinary Internal Medicine (ACVIM), addressed clinical pharmacologic issues on antimicrobial therapy (morning of May 23) and therapy in special patient subgroups (afternoon of May 23). The ACVIM abstract from each presentation appear in these proceedings (with permission from ACVIM and the authors). In addition, most authors kindly provided their Powerpoint slides from their presentations. These slides are reproduced along with a transcription of the presentation where available.

The annual business meetings of the AAVPT and ACVCP were held in conjunction with the symposium.

The Organizing Committee sincerely thanks Pharmacia Animal Health for their financial support of the symposium.

Organizing and Program Committee Members:

Dr. Cory Langston, Chair AAVPT Program Committee
Dr. Debbie Kochevar, Secretary AAVPT
Dr. Cyril Clarke, Chair ACVCP Program Committee
Dr. Jane Owens Clark
Dr. Marilyn Martinez
Dr. Pete Miller

TABLE OF CONTENTS

	<u>page</u>
Challenges Associated with the Evaluation of Veterinary Product Bioequivalence: An AAVPT Perspective <i>Marilyn Martinez, Cory Langston, Tomas Martin, and Dale Conner</i>	1
Supply and Demand of Veterinary Pharmacologists <i>Scott A. Brown</i>	21
Unique Aspects of Veterinary Formulations <i>Kasra Kasraian</i>	30
Challenges in Development of Sustained Release Parenteral Formulations <i>Scott A. Brown</i>	40
Topical/Local vs. Systemic Antimicrobial Therapy <i>Ted Whittam</i>	
ACVIM abstract	43
Slide presentation	49
Rational Use of Bacterial Culture/Sensitivity Data <i>Mike Apley</i>	
ACVIM abstract	56
Slide presentation	60
Update on the Veterinary Antimicrobial Decision System (VADS) ACVIM abstract <i>Mike Apley, Cory Langston, Virginia Fajt</i>	74
Slide presentation: Veterinary Antimicrobial Decision Support System <i>Mike Apley, Virginia Fajt, Cory Langston, Jeff Wilcke, Beth Monroe, and Sarah Bashaw</i>	78
Slide presentation: VADS Modeling of Antibiotic Profiles <i>Cory Langston</i>	84
Slide presentation: VADS System: Creating Virtual Animals And Bacteria <i>Virginia Fajt</i>	92
Multiple Drug Resistance <i>Cyril Clarke</i>	
ACVIM abstract	98
Slide presentation	102
Pharmacotherapeutic Implications of Kidney Failure ACVIM abstract <i>Herve P. Lefebvre</i>	111
Slide presentation <i>Herve Lefebvre, A.D.J. Watson; Pierre-Louis Toutain</i>	118
Special Considerations for Drug Therapy in the Patient with Liver Disease <i>Dawn Boothe</i>	
ACVIM abstract	132
Slide presentation	136

Pharmacotherapy of Neonates And Pregnant Animals

Cory Langston

ACVIM abstract

152

Slide presentation

156

Evidence tables

170

<u>drug</u>	<u>pages</u>	<u>drug</u>	<u>pages</u>
albendazole	170, 171	griseofulvin	176
amikacin	177	indomethacin	196
aminoglycosides (also see individual agents)	176, 177	isoxsuprine	191
ampicillin	177	ivermectin	172
aspirin	194, 200	ketoprofen	197, 198, 200
atropine	173	metaclopramide	192, 193
benazepril	190	metronidazole	184
ceftiofur	178	naproxen	199
chloramphenicol	178	nitrofurantoin	185
ciprofloxacin	179, 185	norfloxacin	179, 185
clenbuterol	189	NSAIDs (also see individual agents)	200
clindamycin	180	ofloxacin	179
digoxin	190	oxfendazole	171
dipyrrone	200	oxytocin	193
doxycycline	181	phenobarbitol	173
erythromycin	181	phenylbutazone	200
ethyl alcohol	184	phenytoin	174
florfenicol	182, 183	pyrimethamine	186
fluconazole	174, 175	quinolones (also see individual agents)	187
flunixin	200	tetracycline	187, 188
flurbiprofen	195	theophylline	189
furosemide	192	trimethoprim	188
gentamicin	177, 180	xylazine	201

Pharmacotherapy of Immunocompromised Animals

Mark Papich

ACVIM abstract

202